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The underlying cause of cognitive decline in VaD (and, therefore, AD+CVD) appears cholinergic dysfunction, as with AD. It is reasonable to expect that acetylcholinesterase inhibitor may be useful in patients with AD+CVD.
Galantamine (Reminyl ® ), a novel cholinergic agent with a unique dual mode of action (an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors), has consistently demonstrated broad benefits on cognition, global function, activities daily living (ADL). In addition to inhibiting acetylcholinesterase, galantamine allosterically modulates neuronal nicotinic receptors. This additional mechanism of action amplifies the actions of acetylcholine (Ach) at pre and postsynaptic nicotinic Ach receptors and, in particular, modulates the release of Ach and other neurotransmitters such as glutamate, serotonin, dopamine and GABA. 3 Randomized clinical trials of Galantamine have shown efficacy on global impression, cognition, ADL, and behavior. [4] [5] [6] There is evidence of some cognitive benefit to patients with mixed Alzheimer's disease and cerebrovascular disease. Slow dose escalation appears to improve tolerability to the drug. [7] [8] [9] [10] The efficacy outcomes for patients with AD+CVD after 12 months treatment of Galantamine, scores remained near baseline level. 10 Cognitive scores of patients AD treated with Acetylcholineesterase Inhibitors Galantamine over a period of 6 months, 16 and 24 mg/day maintained patients' cognitive function above baseline, fall below baseline after 12 months, and experienced appreciably less cognitive decline over 24 months than that seen in placebo control group.
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Adverse events were typically mild as results in all double blind, placebo controlled trials. 4, 5, 7 Recent data have shown that Galantamine improves the early signs of neurodegeneration and reduces amyloid precursor protein vascular deposition in anti nerve growth factor mice. 23 This is the first study of acetylcholinesterase Inhibitor in subject with AD and AD+CVD (Mixed Dementia) to evaluate the efficacy and tolerability of galantamine, 16 mg/day-known protocol GAL-DEM-402 in Indonesia. Patients were excluded from the study if they had evidence of any other neurodegenerative disorders; any cognitive impairment.
METHODS

Patients
Patients with the following co-existing medical conditions were also excluded: Any history of epilepsy, current clinically significant psychiatric disease as judged by DSM-IV criteria, history of drug or alcohol abuse, active peptic ulcer, clinically significant hepatic, renal and pulmonary disturbances, urinary outflow obstruction, cardiovascular disease that would be expected to limit the patient's ability to complete a 6 months trial, history of severe drug allergy or hypersensitivity. Any agent used for the treatment of dementia may not be used after enrolment in this trial. Note: Acetyl Salicylic Acid taken in doses up to 325 mg daily and anti-hypertensive to prevent cardio-or cerebrovascular disease, does not exclude the patient.
Patient also excluded from the trial if they withdraw their consent or the caregiver(s) withdraw the consent. The data were analysed using descriptive statistics and graphical representations.
RESULTS
Based on 18 month screening examination, there were 50 dementia patients, 28 patients were eligible for the study, appropriate to inclusion and exclusion criteria, 2 patients were only had 2 month treatment and subsequently rejected to continue treatment, therefore there were 26 patients who completed the 6 month treatment study.
Patient medical and demographic characteristics are summarized in Table 1 . Among 28 patients, 19 (67%) were AD and 9 (33%) were mixed dementia. Mild dementia patients were found in 13 (46%) of patients and moderate dementia in 15 (54%) of patients. The mean value of cognitive MMSE domains of patients: orientation was 6.1 (total score 10), registration was 3 (total score 3), attention was 2.9 (total score 5), recall memory was 0.5 (total score 3), language was 7.9 (total score 8), and dementia patient with MMSE interval 14-25. The mean NPI value was 4.18 and the mean CDR value was 1.05.
In cognitive evaluation by using Neuropsychology Assessment, the mean value for attention was 5.07, which was within the normal limit, for memory was 3.64 (total score 10), form naming was 12.07 (total score 15), for verbal fluency was 7.50 (normal value for elderly was > 10), for visuoconstruction was 7.07 (total score 11), for memory recall was 0.75 (total score 10) and for recognition memory was 3.75 (total score 10).
Cognition
In evaluation of cognitive function by using MMSE, there was significant difference from baseline data since the 2nd month evaluation ( Figure. 1).
The 6-month Galantamine had a significantly better outcome of cognitive performance, comparable with the baseline data as were assessed using the MMSE (p<0.05), the Restricted Reminding (p<0.05); the Neuropsychology Assessment (p<0.05)
On figure 2, after 6-month treatment, the evaluation on MMSE cognitive domain indicated a better result, which included: orientation, attention, calculation, memory recall and language. 
. Evaluation of cognitive domains from MMSE
Verbal memory has indicated significant difference from baseline data since initial evaluation in last 1 st month ( Figure 3) . Moreover, the evaluation of Neuropsychology Assessment (NA) total score has been also significantly different (Figure 4 ). In the end of 6 th month, the domains of NA, which significantly indicated better result, were: reason memory, verbal fluency, recalls memory and recognition ( Figure 5 ) 
Global function
Initially at the end of 2 nd month, Clinical Dementia Rating (CDR) evaluation was significantly different compared to baseline. The 6-month Galantamine had better significant outcome of global function, with CDR (p<0.05) (Figure 6 ). 
Behavior
Initially at the end of 2 nd month, neuropsychiatry inventory(NPI) evaluation was significantly different compared to the baseline. The 6-month Galantamine had a significant better outcome of behavior changes, the NPI (p<0.05) (Figure 7 ). Non-cognitive symptoms improved significantly on NPI after 6-month treatment was: anxiety, apathy, irritability and night-time behavior (Figure 8 ).
Safety and Tolerability of Galantanine
Adverse event was found in 9 of 28 patients, 7 patients with nausea and 4 patients with anorexia. Adverse event were typically mild and transient, related to dose escalation, with duration less than 1 week.
DISCUSSION
This study is the first efficacy & safety study of acetylcholinesterase inhibitor in AD and mixed Dementia in Indonesia. Current study showed that result in cognitive evaluation with MMSE after 6 month had a significant improvement at: orientation, attention/ calculation, memory recall and language function. Special memory test of RR showed earlier amelioration after 1 month, and so do at total scores of NA after 6 month; all tests of memory at NA (reason memory, recall memory, and recognition memory) significantly amelioration above baseline.
The result of this sub analysis showed that Galantamine (Reminyl  ) is effective in treating the symptoms of memory loss in patients with AD and AD+CVD.
The assessment of global function and behavior alteration indicated significant improvement at the end of 2 nd month evaluation. Therefore, Galantamine effectively improves the global function and behavior alteration not only in AD patients but also in AD+CVD patients.
The adverse events related to the drugs, which occurred after 4-week drug titration is mild, i.e. nausea and anorexia in 9 of 28 cases, and consistent with international data.
The adverse event variation is less than adverse event in previous study. It may be caused by the smaller sample size.
It is concluded that 6 months treatment with galantamine results in significant improvement of cognitive function, memory verbal, behavior symptoms, and global function.
Adverse events were typically mild and transient.
